ÃâÒßѧÊÔÌâ
VR>;{>~ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
{@u;F2? 1. Fas(CD95)/FasL
;2vHdN 2. common chain of cytokine receptor
JBCcR,\kM* 3 . TCR/CD3 complex
*sqq] uD 4. negaive selection of thymocytes
vv
_I o 5. artificial active immune
\k1psqw^O 6. anti-idiotypic
zA&lJD$0 7. IgSF
dlC)&Ai 8. Integrin
M
?4)U"_VE 9. chemokine
b]s*z<|% 10. B7/CD28
M$z.S0" ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
"SyAOOZ 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
\+E{8&TH' 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
VpJ/M(UD- 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
K+D`U6& 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
Us'm9 J
9cAb\5c| 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
0hXI1@8]` µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
oQ= Q} Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
udDhJ? 1. B7/CD28
F
kp;G 2. Th1 subset
z!5^UD8"W 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
#CoJ S[t 4. antibody affinity maturation
&dZ-}.
af 5. AP-1
pGz-5afL 6. single chain variable fragment£¨ScFv£©
6~sb8pK.= 7. NK cell receptor
, gk49z9 8. Zinkernagel-Doherty phenomenon
U7.3`qd" 9. Ig fold
V<AT"vU[ 10. CD40/CD40L
-:`$8/A| ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
'$W@I 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
5bX
SN$7| 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
Jz
s.) 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
j`A%(()d Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
[k.|iCD 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
Ln0rm9FV- 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
3>%rm%ffE 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
Od70w*, Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
)f9f_^; £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
/=A?O
\B7 Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
6wx;grt'Z 1.Co-stimulators (or co-stimulating molecules)
";yCo0* 2.NK-kB
4bqi&h3 3.Immunoglobulin superfamily
j2SJ4tB / 4.antigen-presenting cell (APC)
K O "U5v 5.death domain
bsy\L|wd 6.CCR and CXCR
)#zc$D^U 7.Lectin (or mitogen)
LO<R<zz 8.Clusters of differentiation, CD)
n=l>d#}$%T 9.B7 family
E&P'@'Yk 10.Cytotoxic T lymphocyte, CTL)
Y&KI/]ly,L 11.IL-15 and IL-15 receptor (IL-15R)
Tz3 L#0:j 12.MHC restriction
.)o<'u@Ri 13.Affinity-chromatography
%719h>$ 14.Cyctosprin A, CsA
ra=U, 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
wUj[c7Y
% ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
$L_-U~^ 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
/"?yB$s 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
~wf&78 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
.dX ^3 Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
5xe}ljo ÃâÒßѧרҵ£º
, f{< 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
V/"UDof Ïû»¯ÄÚ¿Æ£º
F8mS5oB|^
2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
$q,2VH :Ip ѪҺ²¡Ñ§×¨Òµ£º
5H#f;L\k 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
7p*PDoM6` Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
n4,b?-E>( (רҵ»ù´¡: ÃâÒßѧ)
=]jc{Y%o Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
U Hh 1. ADCC(antibody dependent cell-mediated cytotoxicity)
,Z*&QR 2. »·æß¾úËØ(cyclosporin)
3y?I^ .B 3. KIR(killer cell inhibitory receptor)
K}7E;O5m" 4. HLDA(human leucocyte differentiation antigen)
Z6C!-a 5. Interleukin 18(IL-18)
E{x<P0 ; 6. ÕûºÏËØ(integrin)
KBJ%$OQV 7. Fas/FasL
|8^53*f ? 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
LkYcAY$w 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
Aiyx!Q6vT 10. Th1/Th2
[Z~h!} 11. »ùÒòÒßÃç(DNAÒßÃç)
mY6d+ 12. chemokines and chemokine receptor
S&(MR%". 13. ÃâÒßÄÍÊÜ
z OwKh>] 14. ¹²´Ì¼¤·Ö×Ó
G*;?&;* 15. ËÀÍö½á¹¹Óò(death domain)
CVUA7eG+ ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
N,k PR 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
9~3;upWu! 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
K9-;-{qb £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
2S%[YR>> £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
<46>v< £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
1M@OBfB8 £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
Rhw- 49AWx 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
v=m!$~ Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
1f}YKT ÎÊ´ðÌâ(ÿÌâ25·Ö)
QjT$.pUd 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
&~4;HjS 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
<O<Kf:i&c1 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
/;5U-<qf 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£